13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001697013
Total reported value
$1.9B
$1.9B
117 檔
30.3%
In Q1 2026, Eversept Partners, LP's U.S. equity holdings reached a combined market value of $1.9B, distributed across 117 disclosed stock positions.
Eversept Partners, LP executed strategic sector rebalancing during Q1 2026, establishing 40 new positions while fully exiting 30 holdings and trimming 37 positions.
In terms of portfolio concentration, the top 5 core holdings (including UTHR, QQQ, ABVX) accounted for 30.3% of total reported equity market value during Q1 2026.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | UTHR | United Therapeutics CORP | Stock-Healthcare | 8.26% | -0.17% | +4.62% | |
| 2 | QQQ | Invesco Qqq Trust Series 1 | ETF-Tech | 7.26% | -3.49% | +6.09% | |
| 3 | ABVX | Abivax Sa-adr | Stock-Other | 5.49% | +0.83% | +42.05% | |
| 4 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 5.20% | -3.89% | -33.38% | |
| 5 | VERA | Vera Therapeutics Inc | Stock-Other | 4.61% | +0.32% | -29.26% | |
| 6 | NTRA | Natera Inc | Stock-Healthcare | 4.06% | -1.58% | +15.01% | |
| 7 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 3.67% | -3.67% | EXIT | |
| 8 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 3.55% | -0.38% | -12.94% | |
| 9 | CLDX | Celldex Therapeutics Inc | Stock-Other | 2.99% | +0.46% | +24.62% | |
| 10 | PCVX | Vaxcyte Inc | Stock-Other | 2.83% | -0.93% | -22.84% | |
| 11 | BKD | Brookdale Senior Living Inc | Stock-Other | 2.57% | +0.27% | +851.79% | |
| 12 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.50% | +0.23% | +17.44% | |
| 13 | QGEN | Qiagen N.V. | Stock-Healthcare | 2.16% | -2.02% | — | |
| 14 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 2.12% | -2.12% | EXIT | |
| 15 | HCA | Hca Healthcare Inc | Stock-Healthcare | 1.98% | +0.01% | -17.36% | |
| 16 | TLT | Ishares 20+ Year Treasury Bd | ETF-Gov Bonds | 1.96% | -1.96% | EXIT | |
| 17 | WELL | Welltower Inc | Stock-Real Estate | 1.89% | -0.86% | — | |
| 18 | DOC | Healthpeak Properties Inc | Stock-Real Estate | 1.72% | -1.72% | EXIT | |
| 19 | PODD | Insulet CORP | Stock-Healthcare | 1.59% | -0.41% | +92.14% | |
| 20 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 1.53% | -0.56% | +1.57% | |
| 21 | GERN | Geron CORP | Stock-Other | 1.48% | -0.24% | +6.65% | |
| 22 | OHI | Omega Healthcare Investors | Stock-Real Estate | 1.35% | -0.15% | — | |
| 23 | LQDA | Liquidia CORP | Stock-Other | 1.35% | +0.42% | +32.97% | |
| 24 | CYH | Community Health Systems Inc | Stock-Other | 1.35% | +0.01% | +9.23% | |
| 25 | AVTR | Avantor Inc | Stock-Healthcare | 1.23% | -1.23% | EXIT | |
| 26 | EHC | Encompass Health CORP | Stock-Healthcare | 0.99% | +4.39% | +81.53% | |
| 27 | LLY | Eli Lilly & Co | Stock-Healthcare | 0.92% | +0.33% | +78.86% | |
| 28 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.85% | +1.50% | -53.82% | |
| 29 | INSM | Insmed Inc | Stock-Healthcare | 0.81% | +0.55% | — | |
| 30 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.79% | -0.10% | +27.18% | |
| 31 | HYG | Ishr Ibx Usd Hiyld Cb Etf-ui | ETF-High Yield | 0.76% | -0.76% | EXIT | |
| 32 | RGEN | Repligen CORP | Stock-Healthcare | 0.75% | -0.65% | — | |
| 33 | BBNX | Beta Bionics Inc | Stock-Other | 0.75% | +0.27% | +108.60% | |
| 34 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.74% | +0.05% | -59.98% | |
| 35 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 0.72% | -0.54% | +32.66% | |
| 36 | ARDX | Ardelyx Inc | Stock-Other | 0.70% | -0.26% | +29.99% | |
| 37 | LTC | Ltc Properties Inc | Stock-Other | 0.63% | +0.21% | — | |
| 38 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 0.62% | +0.12% | +121.62% | |
| 39 | CHE | Chemed CORP | Stock-Healthcare | 0.62% | +0.65% | — | |
| 40 | PHVS | Pharvaris N.V. | Stock-Other | 0.61% | +0.08% | -7.34% | |
| 41 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 0.57% | +0.53% | -34.28% | |
| 42 | IWM | Ishares Russell 2000 ETF | ETF-Small Cap | 0.52% | -0.52% | EXIT | |
| 43 | PNTG | Pennant Group Inc/the | Stock-Other | 0.50% | +0.38% | +6.20% | |
| 44 | XLK | Ss Technology Select Sector | ETF-Tech | 0.49% | -0.49% | EXIT | |
| 45 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.48% | — | -32.09% | |
| 46 | PALI | Palisade Bio Inc | Stock-Other | 0.46% | -0.01% | -7.49% | |
| 47 | MRNA | Moderna Inc | Stock-Healthcare | 0.43% | +0.12% | -40.37% | |
| 48 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.41% | +0.81% | — | |
| 49 | ICLR | ICON Public Limited Company | Stock-Healthcare | 0.40% | -0.40% | EXIT | |
| 50 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.40% | +0.22% | -44.00% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | BKD | Brookdale Senior Living Inc | +2.4% | +851.79% | Add |
| 2 | SPY | Ss Spdr S&p 500 ETF Trust-us | +2.1% | +138.31% | Add |
| 3 | UTHR | United Therapeutics CORP | +2.1% | +4.62% | Add |
| 4 | CLDX | Celldex Therapeutics Inc | +1% | +24.62% | Add |
| 5 | ABVX | Abivax Sa-adr | +1% | +42.05% | Add |
| 6 | TLT | Ishares 20+ Year Treasury Bd | +1% | +86.43% | Add |
| 7 | PODD | Insulet CORP | +0.5% | +92.14% | Add |
| 8 | LQDA | Liquidia CORP | +0.5% | +32.97% | Add |
| 9 | EHC | Encompass Health CORP | +0.4% | +81.53% | Add |
| 10 | BCRX | Biocryst Pharmaceuticals Inc | +0.4% | +1.57% | Add |
| 11 | IONS | Ionis Pharmaceuticals Inc | +0.4% | +17.44% | Add |
| 12 | BMRN | Biomarin Pharmaceutical Inc | +0.3% | +121.62% | Add |
| 13 | LLY | Eli Lilly & Co | +0.3% | +78.86% | Add |
| 14 | GERN | Geron CORP | +0.3% | +6.65% | Add |
| 15 | QQQ | Invesco Qqq Trust Series 1 | +0.3% | +6.09% | Add |
| 16 | CTMX | Cytomx Therapeutics Inc | +0.3% | +27.18% | Add |
| 17 | ARDX | Ardelyx Inc | +0.2% | +29.99% | Add |
| 18 | NTRA | Natera Inc | +0.2% | +15.01% | Add |
| 19 | CYH | Community Health Systems Inc | +0.1% | +9.23% | Add |
| 20 | PNTG | Pennant Group Inc/the | +0.1% | +6.20% | Add |
| 21 | ARQT | Arcutis Biotherapeutics Inc | +0.1% | +32.66% | Add |
| 22 | ALEC | Alector Inc | +0.1% | +34.28% | Add |
| 23 | EHABUSD | Enhabit Inc | +0.1% | +4.09% | Add |
| 24 | SVRA | Savara Inc | +0.1% | +125.78% | Add |
| 25 | PCVX | Vaxcyte Inc | +0.1% | -22.84% | Trim |
| 26 | SNDX | Syndax Pharmaceuticals Inc | 0% | -12.94% | Trim |
| 27 | WHWK | Whitehawk Therapeutics Inc | 0% | +17.88% | Add |
| 28 | MRNA | Moderna Inc | 0% | -40.37% | Trim |
| 29 | CTNM | Contineum Therapeutics Inc-a | 0% | +6.49% | Add |
| 30 | SSII | Ss Innovations International | 0% | +46.18% | Add |
| 31 | EDIT | Editas Medicine Inc | 0% | — | Unchanged |
| 32 | PLRX | Pliant Therapeutics Inc | 0% | +5.87% | Add |
| 33 | PHVS | Pharvaris N.V. | — | -7.34% | Trim |
| 34 | NVCR | NovoCure Limited | — | +11.52% | Add |
| 35 | RVP | Retractable Technologies Inc | — | — | Unchanged |
| 36 | INMD | InMode Ltd. | — | +9.37% | Add |
| 37 | STRO | Sutro Biopharma Inc | 0% | -62.20% | Trim |
| 38 | BCYC | Bicycle Therapeutics Plc-adr | 0% | +6.60% | Add |
| 39 | AVR | Anteris Technologies Global | 0% | -19.76% | Trim |
| 40 | AMRN | Amarin CORP PLC -adr | 0% | -14.21% | Trim |
| 41 | IFRX | InflaRx N.V. | 0% | +0.07% | Add |
| 42 | SRZN | Surrozen Inc | 0% | -38.48% | Trim |
| 43 | SLQT | Selectquote Inc | 0% | — | Unchanged |
| 44 | EHTH | Ehealth Inc | 0% | -0.74% | Trim |
| 45 | ✓ | Engene Holdings Inc | 0% | +12.00% | Add |
| 46 | PASG | Passage Bio Inc | 0% | +4.24% | Add |
| 47 | RLAY | Relay Therapeutics Inc | -0.1% | -44.66% | Trim |
| 48 | SPRY | Ars Pharmaceuticals Inc | -0.1% | -45.85% | Trim |
| 49 | GPCR | Structure Therapeutics Inc | -0.1% | +8.21% | Add |
| 50 | BVS | Bioventus Inc - A | -0.1% | -66.24% | Trim |
According to official SEC Form 13F filings, Eversept Partners, LP reported a total U.S. public equity portfolio value of $1.9B across 117 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
QGEN
市值: $40.9M
Top Position Liquidated / Trimmed
DHR
前期市值: $42.6M
During Q1 2026, Eversept Partners, LP's top holdings by market value included UTHR (8.3%)、QQQ (7.3%)、ABVX (5.5%). The largest single position, UTHR, represented 8.3% of total portfolio value.
In Q1 2026, Eversept Partners, LP made 144 total portfolio adjustments, initiating 40 new buys, adding to 37 positions, trimming 37 holdings, and fully liquidating 30 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.